MoneyWorks4Me

Alembic Pharmaceuticals informs about press release

10 Jun 2022 Evaluate

Alembic Pharmaceuticals has informed the exchange that the Company has received US Food & Drug Administration (USFDA) Tentative Approval for Dasatinib Tablets, 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg. In this regard, the company has attached a press release.

The above information is a part of company’s filings submitted to BSE.

Peers
Company Name CMP
Sun Pharma. Inds. 1835.50
Dr. Reddys Labs. 1171.10
Cipla 1371.45
Lupin 2144.70
Zydus Lifesciences 1153.00
View more..